Method of producing 9-(1,3-dioxy-2-propoxymethyl) guanine

专利摘要:
U. METHOD OF OBTAINING 9-
公开号:SU1176841A3
申请号:SU823443852
申请日:1982-05-20
公开日:1985-08-30
发明作者:П.Верхейден Джульен；С.Мартин Джон
申请人:Синтекс (Ю.С.А.) Инк (Фирма)；
IPC主号:

专利说明:

The invention relates to a process for the preparation of 9- (1, 3-dioxy-2-propoxymethyl) guanine, based on a known method and its salts, alkali metals, having anti-oil activity HN-Y A, / - NJ-Ng. .No I HO-VX. The aim of the invention is to obtain a novel compound 9- (1,3-wild-sig2-propoxymethyl) guanine, which has advantages in antiviral activity as compared with structural analogues of the same effect. Example I. (A) Preparation of N-acetyl-9- (1,3-dibenzyloxy-2-propimethyl) guanine, N 9-diacetylguanine (15.61 g, 66 mmol), 2-0-acetoxymethyl-1,3-di-benz Ilglycerol (19 g, 55 mmol) and. Bis (p-nitrophenyl) phosphate (0.5 g) is stirred together with 150 ml of diethyl ether. The solvent is distilled off and the residue is heated at 175 ° C in an oil bath for 1.5 hours to a stream of nitrogen. Chromatography on the column is followed by eluting with methanol / methylene chloride (1: 9) and subsequent recrystallization; from ethyl acetate give 4.76 g of N -detyl-9- (1, 3-Dibenzyloxy-2-pro poxymethyl) guanine, so pl. 145-14bc (B) Preparation of N-acetyl-9- (1,3-dioxy-2-propoxymethyl) guanine. To a solution of N-acetses1-9- (1,3-dibenzyloxy-2-propoxymethyl) guanine (4.62 g, 9.67 mmol) in 150 ml methane. lal pliss 40 ml of water 20% palladium hydroxide on carbon is added as a suspension in 10 ml of water. The mixture is hydrogenated in hydrogenation. Parr at a hydrogen pressure of 4.2 kg / cm for 38 hours is then filtered through a mixture and concentrated to a white solid. Recrystallization from methanol / ethyl acetate gives 1.4 g of N-acetyl-9- (1, 3-dioxy-2-propoxymethyl) guanine, m.p. 205-208s. The solution was then reduced to P% palladium on carbon (1 g) in 150 ml of methanol plus 50 ml of water at 60 psi, inch (4.2 kg / cm) for 47 hours. Total yield of N-adhetil-9- ( 1, 3-dioxy-2-propoxymethyl) guanine is 2.11 g, (c) Preparation of 9- (1,3-dioxy-2-propoxymethyl) guanine. N-acetyl-9- (1,3-dioxy-2-propoxymethyl) guanine (721.9 mg, 2.4 mmol) is stirred with 50 ml of a methanolic ammonia solution (methanol, saturated with ammonia at 0 C) for 17 h, at 21 ° C. The solution is concentrated to a white solid, and the residue is recrystallized from methanol to give 582.3 mg of 9- (1,3-dioxy-2-propoxymethyl) guanine, mp 250 C (with decomposition), and . 2. 9- (1 3-dioxy-2-propoxymethyl) guanine is dissolved in an aqueous solution containing one mole equivalent of sodium hydroxide. The solution is then lyophilized to obtain the sodium salt of 9- (1,3-dioxy-2-propoxymethyl) guanine as a white powder: UV: 71 days 265 mm; 1 11400. Example 3. Sodium salt of 9- (1, 3-dioxy-2-propoxymethyl) guanine is dissolved in a minimal amount of water and diluted hydrochloric acid is added to bring the pH to 7, 9- (1, 3- dioxy-2-propoxymethyl) guanine. m.p. , Example 4, To a solution of sodium salt of 9- (1,3-dioxy-2-propoxymethyl) guanine (0.83 g, 3 mmol) in water (10 ml) is added ammonium chloride (0.48 g, 9 mmol) and the resulting solution is cooled to .OC. The resulting crystals are filtered and dried. They are then dissolved in 100 ml of water containing KOH (O, 17 g, 3 mmol). The resulting solution is frozen and then lyophilized to obtain the potassium salt of 9- (1,3-dihydrox-2-propoxymethyl) guanine. Example 5 To a solution of sodium salt of 9- (1,3-dioxy-2-propoxymethyl) guanine (0.83 g, 3 mmol) in water (10 ml) was added ammonium chloride (0.48 g, 9 mmol) and the resulting solution is cooled to O C. The crystals are filtered, vacuum dried and then concentrated from N N-dimethylformamide (10 ml) and the residue is reacted with hexamethyldisilane- (5 ml) in KH-dimethyl3 formamide (10 ml) for 5 hours with the following addition of pyridine (10 m and isobutyl anhydride (10 ml). The resulting solution is stirred for 18 h. Then methanol is added (20 ml). The solution is evaporated to and approximately 15 ml and the product is precipitated by adding 1: 1 ratio of hexane diethyl ether solution (50 ml. The precipitate is recrystallized from 2: 1 methanol / soda, to give 9- (1, 3-dioxy-2-propoxymethyl) guanine. 2 Example 6. A solution of N-acetyl-9- (1, 3-dioxy-2-propoxymethyl) guanine (0.89 g, 3 mmol) in methanol (40 ml) was added to a concentrated solution of ammonium hydroxide (10 ml ), stirred for 24 hours at room temperature, then concentrated and the precipitate subjected to vacuum drying. The residue is then dissolved in water (100 ml) containing NaOH (0.12 g, 3 mmol), the resulting solution is extruded and amofilized to obtain the sodium salt of 9- (1,3-dioxy-2-propoxymethyl) guanine. Example. The exceptional antiviral activity of the compound according to the invention is illustrated with the following data. In cell cultures, Hep-2 prepare the Negrex virus sineplex strain 6 for infection. The virus is adsorbed for 1 h, fresh medium is placed on the cells and everything is incubated at 35 ° C until all cells are infected. The cell suspension is frozen at (-70 ° C from thawing and centrifuged to remove cellular debris .. The sedimentation fluid is drained and stored in a frozen ice-free state at (-70) ° C, 1.0 dilution of the supernatant gives a 50% infectious dose 50% cell culture (CCIDEQ) in HEp-2 cells and 10 dilution gives 50% lethal: EXODUS (C JQ) on mice. Groups of 20 smaller Swiss Webstev O 5-1 7 g / infect: intraperitoneally using 0.2 ml of EMEM containing 10 virus in the D-mouse, Msggei is infected 10 times with the amount of virus more than the dose of 10, Dj (serving as a control for virulence, which is done to ensure the performance of the model. Treatment with test compounds is started 6 hours after infection. Mushrooms divided into groups of 20 individuals are administered compounds in saline 5 mg / kg, 10 mg / kg and 20 mg / kg. One group of 20 individuals is used as a control and receives saline. Baking is repeated 24, 48, 72 and 96 hours after infection. Test compounds: A compound according to the invention and three compounds described in U.S. Pat. No. 4,199,574, which have a partial structural similarity to the compound according to the invention (table). The results show a comparison between the number of surviving animals that received the compound according to the invention and the number of surviving animals that received the three known compounds, which gives a clear idea of the extremely high antiviral activity of the described compound.
Control / (without treatment) O- (I, 3-Dibenzoxy-2-prop. 0

权利要求:
Claims (1)
[1]
. METHOD FOR PRODUCING 9- (1,3-DI0XSI-2-PR0P0XIMETHYL) GUANICH general formula I
On he or its salts with alkali metals, which consists in that the compound of formula _e gidrolizuyut- XT - S
OH where R is lower alkyl, to give 9- (1, 3-dioxi-2-propoxymethyl) guanine and, if necessary, convert 9- (1, 3-dioxi-2-propoxymethyl) guanines an alkali metal salt or exchange an alkali metal cation in the salt of 9- (1,3-dioxi-2-propoxymethyl) guanine.
IWTT>

类似技术:

---

公开号 | 公开日 | 专利标题

---

SU1176841A3|1985-08-30|Method of producing 9-| guanine

---

EP0312858B1|1992-02-05|Heterocyclic derivatives, their preparation and radiosensitizing agents and antiviral agents comprising same as their active component

---

US4547567A|1985-10-15|Derivatives of 4'-demethyl-4-epipodophyllotoxin

---

US4525299A|1985-06-25|-15-Deoxyspergualin, process for the preparation thereof, and intermediate of the same

---

DK148745B|1985-09-16|RIBOFURANOSYL DERIVATIVES USED AS INTERMEDIATES IN THE PREPARATION OF 5'-DEOXY-5-FLUORCYTIDINE OR 5'-DEOXY-5-FLUORURIDINE OR PHYSIOLOGICALLY TOLERABLE ACID ADDITIONAL SALTS

---

SU1561826A3|1990-04-30|Method of producing carbocyclic purine nucleosides

---

US3856777A|1974-12-24|Method of producing pyrimidine nucleoside derivatives

---

US4188377A|1980-02-12|Carminomycin derivatives, their preparation and use

---

US4267326A|1981-05-12|Uracil derivatives

---

CA1101855A|1981-05-26|Purine derivatives

---

US4914028A|1990-04-03|Method of preparing beta-2',2'-difluoronucleosides

---

Adlersberg et al.1964|Synthesis of 3, 7-dideoxy-d-threo-hepto-2, 6-diulosonic acid: a study in 5-dehydroquinic acid formation

---

SU650507A3|1979-02-28|Method of obtaining glycoside antibiotics or their hydrochlorides

---

US4751293A|1988-06-14|Process for preparation of N6 -substituted 3',5'-cyclic adenosine monophosphate and salt thereof

---

SU991951A3|1983-01-23|Process for preparing 9-|-guanine phosphates

---

KR950008971B1|1995-08-10|Preparation of alpha-n-chypoxanthin-9-yl)-pentyloxy|-arginine

---

RU1779243C|1992-11-30|Process for producing 3-fluoro-4-aminophenol

---

JPS60204742A|1985-10-16|Preparation of tetrafluoro-4-hydroxybenzoic acid

---

Tokuyama1964|Sorboses. V. The Reactions of the Tosyloxy Groups of 2, 3-O-Isopropylidene-α-L-sorbofuranoses in Liquid Ammonia

---

DK170051B1|1995-05-08|14-Chlordaunomycin and acid addition salts thereof, process for the preparation of | -4'-O-tetrahydropyranyladriamycin and | -14-chloro-4'-O-tetrahydropyranyldunomycin

---

CN109206465B|2021-08-27|Method for synthesizing adenosine cyclophosphate

---

SU629213A1|1978-10-25|Method of obtaining alkaline or alkaline-earth salts of s-sulfopanteine

---

US3948883A|1976-04-06|Synthesis of purine nucleosides

---

US4686292A|1987-08-11|Benzo[α]phenazine antitumor agents

---

US3161655A|1964-12-15|3-alkyl-3-amino-6-hydroxy-3, 4-dihydro-coumarins

同族专利:

---

公开号 | 公开日

---

DK150304C|1988-01-04|

---

PL242101A1|1984-07-16|

---

ES8505681A1|1985-06-16|

---

PL136332B1|1986-02-28|

---

LU88334I2|1994-09-09|

---

IN156469B|1985-08-10|

---

CA1305139C|1992-07-14|

---

PH17975A|1985-02-22|

---

GR76459B|1984-08-10|

---

NO161740C|1989-09-20|

---

NZ200691A|1986-11-12|

---

JPH046195B2|1992-02-05|

---

RO87387B|1985-08-31|

---

PT74934A|1982-06-01|

---

HK67088A|1988-09-02|

---

DK504183A|1983-11-03|

---

DK504183D0|1983-11-03|

---

PL136004B1|1986-01-31|

---

FI821794A0|1982-05-20|

---

ES520849A0|1984-11-01|

---

CS235043B2|1985-04-16|

---

AU8389282A|1982-11-25|

---

NO1994005I1|1994-07-29|

---

ES533821A0|1985-06-16|

---

DK227782A|1982-11-22|

---

CA1305141C|1992-07-14|

---

PL242100A1|1984-04-24|

---

NL930022I1|1993-05-03|

---

DK149001C|1988-11-28|

---

CS235042B2|1985-04-16|

---

PT74934B|1984-05-08|

---

HU188000B|1986-03-28|

---

ES512414A0|1984-05-01|

---

DK149001B|1985-12-16|

---

ES8507549A1|1985-09-16|

---

HU186514B|1985-08-28|

---

US4355032B2|1990-10-30|

---

DD203052A5|1983-10-12|

---

DD213218A5|1984-09-05|

---

ES8500276A1|1984-11-01|

---

IE821210L|1982-11-21|

---

AT15899T|1985-10-15|

---

EP0066208A1|1982-12-08|

---

ES8606869A1|1986-05-16|

---

NL930139I2|1997-07-01|

---

JPS57203086A|1982-12-13|

---

JPH0529399B2|1993-04-30|

---

AU572086B2|1988-05-05|

---

PL136637B1|1986-03-31|

---

FI73682B|1987-07-31|

---

ES8404355A1|1984-05-01|

---

IL65836A|1991-04-15|

---

PL236521A1|1984-01-02|

---

RO84860A|1984-09-29|

---

CS235044B2|1985-04-16|

---

ES524900A0|1985-11-16|

---

KR890004663B1|1989-11-24|

---

JPH04217983A|1992-08-07|

---

ES529383A0|1986-05-16|

---

IL65836D0|1982-08-31|

---

PL246770A1|1984-08-27|

---

SG81687G|1989-07-07|

---

DK150304B|1987-02-02|

---

EP0066208B1|1985-10-02|

---

FI73682C|1987-11-09|

---

IE53731B1|1989-02-01|

---

BR8202931A|1983-05-03|

---

ZA823532B|1983-03-30|

---

RO87387A|1985-08-31|

---

NL930139I1|1993-11-01|

---

US4355032A|1982-10-19|

---

KR830010112A|1983-12-26|

---

MY8700793A|1987-12-31|

---

NO821676L|1982-11-22|

---

AR244227A1|1993-10-29|

---

PL136579B1|1986-02-28|

---

ES8701496A1|1987-01-01|

---

DE3266644D1|1985-11-07|

---

ES529384A0|1987-01-01|

---

ES524899A0|1985-09-16|

---

CA1305140C|1992-07-14|

---

CS235018B2|1985-04-16|

---

NO161740B|1989-06-12|

---

ES8601204A1|1985-11-16|

---

US4355032B1|1983-06-14|

---

RO84860B|1984-10-30|

引用文献:

---

公开号 | 申请日 | 公开日 | 申请人 | 专利标题

---

---

US4199574A|1974-09-02|1980-04-22|Burroughs Wellcome Co.|Methods and compositions for treating viral infections and guanine acyclic nucleosides|

---

GB1523865A|1974-09-02|1978-09-06|Wellcome Found|Purine compunds and salts thereof|

---

US4060616A|1976-03-01|1977-11-29|Burroughs Wellcome Co.|Purine derivatives with repeating unit|

---

US4221910A|1978-09-15|1980-09-09|Newport Pharmaceuticals International, Inc.|9-purines|

---

US4347360B1|1980-09-16|1985-10-08|

---

AU7938482A|1980-12-22|1982-07-20|Astra Lakemedel Aktiebolag|Novel derivatives of guanine|

---

PL247394A1|1981-08-11|1984-10-22|Wellcome Found|Process for preparing derivatives of purine|US4508898A|1980-09-16|1985-04-02|Ogilvie Kelvin K|Antiviral triazine compounds|

---

US5157120A|1980-09-16|1992-10-20|SyntexInc.|Guanine derivatives|

---

US4347360B1|1980-09-16|1985-10-08|

---

US4507305A|1981-05-21|1985-03-26|SyntexInc.|9-guanine as antiviral agent|

---

US4423050A|1981-05-21|1983-12-27|SyntexInc.|9-guanine as antiviral agent|

---

PL247394A1|1981-08-11|1984-10-22|Wellcome Found|Process for preparing derivatives of purine|

---

NZ201662A|1981-08-26|1986-07-11|Merck & Co Inc|9--dihydroxy-1--propoxy-methyl)guanine derivatives and methods for their preparation|

---

IE830186L|1982-02-01|1983-08-01|Syntex Inc|Purines|

---

US5250535A|1982-02-01|1993-10-05|Syntex Inc.|Substituted 9- purines as antiviral agent|

---

US4902678A|1982-02-12|1990-02-20|SyntexInc.|Anti-viral compositions|

---

US4609662A|1982-10-14|1986-09-02|Burroughs Wellcome Co.|Method for using purine derivatives|

---

US4462986A|1982-11-04|1984-07-31|Ens Bio Logicals, Inc.|Synergistic anti-herpes compositions|

---

US4814335A|1982-12-30|1989-03-21|Biomeasure, Incorporated|Antiviral compounds|

---

US4461757A|1983-02-23|1984-07-24|Ens Bio Logicals Inc.|Dimethylaminomethylenated anti-herpes compounds|

---

US5047533A|1983-05-24|1991-09-10|Sri International|Acyclic purine phosphonate nucleotide analogs|

---

US4880820A|1983-06-24|1989-11-14|Merck & Co., Inc.|Guanine derivatives|

---

GB8320308D0|1983-07-28|1983-09-01|Wellcome Found|Antiviral combinations|

---

EP0138683A3|1983-09-30|1988-01-20|Merck & Co. Inc.|Purine derivatives, their application in anti-viral compositions|

---

US4897479A|1983-09-30|1990-01-30|Merck & Co., Inc.|Arylsulfonyloxy purine intermediates|

---

IE842642L|1983-10-31|1985-04-30|Harvard College|Purine Derivatives|

---

IL73682A|1983-12-20|1991-08-16|Medivir Ab|Antiviral pharmaceutical compositions containing 9-hydroxy aliphatic derivatives of guanine,some new such derivatives and process for their preparation|

---

US4621140A|1984-02-23|1986-11-04|SyntexInc.|Process for preparing 2,6-substituted-9--purines and certain derivatives|

---

US4579849A|1984-04-06|1986-04-01|Merck & Co., Inc.|N-alkylguanine acyclonucleosides as antiviral agents|

---

EP0190123A1|1984-07-20|1986-08-13|GAUNTT, Charles, O.|Immunoregulatory and anti-viral compound|

---

US4806642A|1984-10-05|1989-02-21|Warner-Lambert Company|Purine derivatives|

---

EP0187297B1|1984-12-12|1991-08-21|SyntexInc.|Alkoxy methyl ether and alkoxy methyl ester derivatives|

---

SE8406538D0|1984-12-21|1984-12-21|Astra Laekemedel Ab|NOVEL DERIVATIVES OF PURINE|

---

US4642346A|1985-06-24|1987-02-10|SyntexInc.|Anhydrous crystalline 9-guanine|

---

US4863927A|1987-05-11|1989-09-05|Merck & Co., Inc.|1-cycloalkylmethyl)-5-substituted uracils|

---

DE10299039I1|1988-12-19|2003-02-20|Wellcome Found|Antiviral pyrimidine and purine compounds Process for their preparation and pharmaceutical preparations containing them|

---

US5068119A|1990-09-28|1991-11-26|Nabisco Brands, Inc.|Acid-hydrolyzable ester derivatives as low calorie fat mimetics|

---

GB2260319B|1991-10-07|1995-12-06|Norsk Hydro As|Acyl derivatives of nucleosides and nucleoside analogues having anti-viral activity|

---

US5627185A|1994-11-23|1997-05-06|Gosselin; Gilles|Acyclovir derivatives as antiviral agents|

---

AU679763B2|1993-06-23|1997-07-10|Merrell Pharmaceuticals Inc.|Carbo-acyclic nucleoside derivatives as antiviral and antineoplastic agents|

---

US5543414A|1994-07-28|1996-08-06|SyntexInc.|Achiral amino acid acyl esters of ganciclovir and its derivatives|

---

US5840891A|1994-07-28|1998-11-24|SyntexInc.|2- methoxy-1,3-propanediol derivative|

---

US5565565A|1994-08-04|1996-10-15|SyntexInc.|Preparation of N-9 substituted guanine compounds|

---

US5840763A|1994-12-12|1998-11-24|Smithkline Beecham Plc|Treatment of a latent infection of herpes viruses|

---

DE19536164A1|1995-09-28|1997-04-03|Boehringer Ingelheim Kg|Improved Process for the Production of 9 - [ methyl] guanine |

---

US5700936A|1996-01-26|1997-12-23|SyntexInc.|Process for preparing a 2- methoxy-1,3-propanediol valinate|

---

US5756736A|1996-01-26|1998-05-26|SyntexInc.|Process for preparing a 2-methoxy-1,3-propanediol derivative|

---

US5840890A|1996-01-26|1998-11-24|SyntexInc.|Process for preparing a 2-methoxy-1,3-propanediol derivative|

---

US6040446A|1996-01-26|2000-03-21|SyntexInc.|Process for preparing a 2- methoxy-1,3-propanediol derivative|

---

IN179493B|1996-02-22|1997-10-11|Lupin Laboraties Ltd|

---

EP0806425B1|1996-04-09|2001-08-29|Lupin Laboratories Limited|An improved regiospecific process for synthesis of acyclic nucleosides|

---

US5852208A|1996-08-30|1998-12-22|Dixie Chemical Company, Inc.|Method of producing compounds containing acyloxyalkoxy groups from alcohols|

---

JP4625637B2|2002-02-22|2011-02-02|シャイアエルエルシー|Active substance delivery system and method for protecting and administering an active substance|

---

CN1091445C|1999-12-29|2002-09-25|湖北省医药工业研究院|Internmediate of anti viral medicine, their preparation and use|

---

US20060189565A1|2002-10-22|2006-08-24|Mathur Rajeev S|Pharmaceutical compositions of ganciclovir|

---

WO2004039808A2|2002-10-31|2004-05-13|Ranbaxy Laboratories Limited|Process for the preparation of ganciclovir|

---

WO2004048380A1|2002-11-22|2004-06-10|Ranbaxy Laboratories Limited|Process for the synthesis of ganciclovir|

---

NZ540728A|2003-01-14|2008-08-29|Gilead Sciences Inc|Compositions and methods for combination antiviral therapy|

---

ITMI20031202A1|2003-06-13|2004-12-14|Lyogen Ltd|CRYSTALLINE SHAPE OF THE GANCICLOVIR|

---

BRPI0413331A|2003-08-28|2006-10-10|Ranbaxy Lab Ltd|amorphous valganciclovir hydrochloride, pharmaceutical composition containing the same and process for its preparation|

---

JP4746866B2|2004-11-19|2011-08-10|Ｔｃｍ株式会社|Backlash prevention device for carriage|

---

TWI471145B|2005-06-13|2015-02-01|Bristol Myers Squibb & Gilead Sciences Llc|Unitary pharmaceutical dosage form|

---

TWI375560B|2005-06-13|2012-11-01|Gilead Sciences Inc|Composition comprising dry granulated emtricitabine and tenofovir df and method for making the same|

---

EP2085397A1|2008-01-21|2009-08-05|Esteve Quimica, S.A.|Crystalline form of abacavir|

---

WO2009120358A1|2008-03-27|2009-10-01|Nektar Therapeutics|Oligomer-nitrogenous base conjugates|

---

US8173621B2|2008-06-11|2012-05-08|Gilead Pharmasset Llc|Nucleoside cyclicphosphates|

---

TW201026716A|2008-12-23|2010-07-16|Pharmasset Inc|Nucleoside analogs|

---

SG172359A1|2008-12-23|2011-07-28|Pharmasset Inc|Nucleoside phosphoramidates|

---

KR20110104074A|2008-12-23|2011-09-21|파마셋 인코포레이티드|Synthesis of purine nucleosides|

---

CN101851239B|2009-04-03|2012-11-28|上海益威实业有限公司|Ganciclovir recovery method|

---

NZ603232A|2010-03-31|2015-02-27|Gilead Pharmasset Llc|Nucleoside phosphoramidates|

---

WO2012154698A2|2011-05-06|2012-11-15|Mckenna Charles E|Method to improve antiviral activity of nucleotide analogue drugs|

---

CN102627643B|2012-04-10|2014-01-08|常州康丽制药有限公司|Refining method for ganciclovir|

---

CA2889903C|2012-10-29|2021-03-09|Manjinder Singh Phull|Antiviral phosphonate analogues and process for preparation thereof|

---

US9505775B2|2012-11-03|2016-11-29|Boehringer Ingelheim International Gmbh|Inhibitors of cytomegalovirus|

---

CN103059023B|2012-12-31|2015-09-30|浙江车头制药股份有限公司|A kind of method preparing ganciclovir crystal form II|

---

US9486530B1|2013-08-30|2016-11-08|Exela Pharma Sciences, LLC|Ganciclovir compositions and related methods|

---

WO2021209563A1|2020-04-16|2021-10-21|Som Innovation Biotech, S.A.|Compounds for use in the treatment of viral infections by respiratory syndrome-related coronavirus|

法律状态:

优先权:

---

申请号 | 申请日 | 专利标题

---

US06267210|US4355032B2|1981-05-21|1981-05-21|9-guanine as antiviral agent|

---